NGL Fine-Chem Ltd's earnings have grown by 36.7%, whereas share price has appreciated 53% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.
NGL Fine-Chem Ltd share price has appreciated 68.6% annually (CAGR) over the past ten years.
Data is not available for this company.
NGL Fine-chem is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.
Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.
Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand
Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.
It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.
NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.
Product range of the company includes:
Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:
An ISO 9001:2000 accredited company